StemCell Institute Inc. (TYO:7096)

StemCell Institute Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	2,679	2,481	2,091	1,781	1,409
Revenue Growth (YoY)	7.98%	18.65%	17.41%	26.40%	-15.93%
Cost of Revenue	987	905	755	670	485
Gross Profit	1,692	1,576	1,336	1,111	924
Selling, General & Admin	1,273	1,142	1,024	874	829
Operating Expenses	1,273	1,162	1,038	884	837
Operating Income	419	414	298	227	87
Interest Expense	-1	-	-	-	-
Interest & Investment Income	10	3	1	-	-
Other Non Operating Income (Expenses)	-	-1	-	-16	4
EBT Excluding Unusual Items	428	416	299	211	91
Gain (Loss) on Sale of Investments	136	22	-	-	-
Other Unusual Items	-	2	-21	-	-
Pretax Income	564	440	278	211	91
Income Tax Expense	179	130	80	78	29
Net Income	385	310	198	133	62
Net Income to Common	385	310	198	133	62
Net Income Growth	24.19%	56.57%	48.87%	114.52%	-77.62%
Shares Outstanding (Basic)	10	10	10	5	5
Shares Outstanding (Diluted)	10	10	10	5	5
Shares Change (YoY)	-0.05%	-	102.33%	4.05%	-
EPS (Basic)	37.59	30.25	19.32	26.26	12.74
EPS (Diluted)	37.59	30.25	19.32	26.26	12.74
EPS Growth	24.25%	56.57%	-26.42%	106.16%	-77.62%
Free Cash Flow	-11	151	43	288	-164
Free Cash Flow Per Share	-1.07	14.74	4.20	56.87	-33.70
Gross Margin	63.16%	63.52%	63.89%	62.38%	65.58%
Operating Margin	15.64%	16.69%	14.25%	12.75%	6.17%
Profit Margin	14.37%	12.50%	9.47%	7.47%	4.40%
Free Cash Flow Margin	-0.41%	6.09%	2.06%	16.17%	-11.64%
EBITDA	547	534	402	323	119
EBITDA Margin	20.42%	21.52%	19.23%	18.14%	8.45%
D&A For EBITDA	128	120	104	96	32
EBIT	419	414	298	227	87
EBIT Margin	15.64%	16.69%	14.25%	12.75%	6.17%
Effective Tax Rate	31.74%	29.54%	28.78%	36.97%	31.87%
Advertising Expenses	-	196	194	175	166

Source: S&P Global Market Intelligence. Standard template. Financial Sources.